Top

Published in:

01-01-2000 | CLINICAL TRIAL REPORT

Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study

Authors: Ofer Merimsky, Isaac Meller, Gidon Flusser, Yehuda Kollender, Josephine Issakov, Miriam Weil-Ben-Arush, Eyal Fenig, Gad Neuman, Dov Sapir, Shmuel Ariad, Moshe Inbar, for the Israeli Soft Tissue and Bone Sarcoma Treatment Groups

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2000

Title: Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study
Authors: Ofer Merimsky
Isaac Meller
Gidon Flusser
Yehuda Kollender
Josephine Issakov
Miriam Weil-Ben-Arush
Eyal Fenig
Gad Neuman
Dov Sapir
Shmuel Ariad
Moshe Inbar
for the Israeli Soft Tissue and Bone Sarcoma Treatment Groups
Publication date: 01-01-2000
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2000
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s002800050027

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2/2000

Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme

Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen

Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation

Different microtubule network alterations induced by pachymatismin, a new marine glycoprotein, on two prostatic cell lines

Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer